The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma

Cancer Cell

Volumn 22, Issue 1, 2012, Pages 117-130

  Berry, Teeara ^a   Luther, William ^b   Bhatnagar, Namrata ^b   Jamin, Yann ^a   Poon, Evon ^a   Sanda, Takaomi ^b   Pei, Desheng ^b   Sharma, Bandana ^b   Vetharoy, Winston R ^a   Hallsworth, Albert ^a   Ahmad, Zai ^a   Barker, Karen ^a   Moreau, Lisa ^b   Webber, Hannah ^a   Wang, Wenchao ^b   Liu, Qingsong ^b   Perez Atayde, Antonio ^c   Rodig, Scott ^b   Cheung, Nai Kong ^d   Raynaud, Florence ^a   Hallberg, Bengt ^e   Robinson, Simon P ^a   Gray, Nathanael S ^b   Pearson, Andrew D J ^a,f   Eccles, Suzanne A ^a   Chesler, Louis ^a,f   George, Rani E ^b   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UMEÅ UNIVERSITY   (Sweden)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN P53; TORIN2; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE MUTATION; GENE OVEREXPRESSION; IC 50; IN VITRO STUDY; MOUSE; MYCN GENE; NEUROBLASTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; UPREGULATION;

EID: 84863753157     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.06.001     Document Type: Article

References (44)

1. Arvanitis C., Felsher D.W. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin. Cancer Biol. 2006, 16:313-317.
2. Banerjee S.A., Hoppe P., Brilliant M., Chikaraishi D.M. 5' flanking sequences of the rat tyrosine hydroxylase gene target accurate tissue-specific, developmental, and transsynaptic expression in transgenic mice. J. Neurosci. 1992, 12:4460-4467.
3. Bresler S.C., Wood A.C., Haglund E.A., Courtright J., Belcastro L.T., Plegaria J.S., Cole K., Toporovskaya Y., Zhao H., Carpenter E.L., et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci. Transl. Med. 2011, 3:108-114.
4. Brodeur G.M., Seeger R.C., Schwab M., Varmus H.E., Bishop J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984, 224:1121-1124.
5. Butrynski J.E., D'Adamo D.R., Hornick J.L., Dal Cin P., Antonescu C.R., Jhanwar S.C., Ladanyi M., Capelletti M., Rodig S.J., Ramaiya N., et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 2010, 363:1727-1733.
6. Chanthery Y.H., Gustafson W.C., Itsara M., Persson A., Hackett C.S., Grimmer M., Charron E., Yakovenko S., Kim G., Matthay K.K., Weiss W.A. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci. Transl. Med. 2012, 4. 115-113.
7. Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L., Soda M., Kikuchi A., Igarashi T., et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974.
8. Chesler L., Schlieve C., Goldenberg D.D., Kenney A., Kim G., McMillan A., Matthay K.K., Rowitch D., Weiss W.A. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 2006, 66:8139-8146.
9. Chiarle R., Voena C., Ambrogio C., Piva R., Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat. Rev. Cancer 2008, 8:11-23.
10. Christensen J.G., Zou H.Y., Arango M.E., Li Q., Lee J.H., McDonnell S.R., Yamazaki S., Alton G.R., Mroczkowski B., Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 2007, 6:3314-3322.
11. Cohn S.L., London W.B., Huang D., Katzenstein H.M., Salwen H.R., Reinhart T., Madafiglio J., Marshall G.M., Norris M.D., Haber M. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J. Clin. Oncol. 2000, 18:3604-3613.
12. De Brouwer S., De Preter K., Kumps C., Zabrocki P., Porcu M., Westerhout E.M., Lakeman A., Vandesompele J., Hoebeeck J., Van Maerken T., et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin. Cancer Res. 2010, 16:4353-4362.
13. George R.E., Sanda T., Hanna M., Fröhling S., Luther W., Zhang J., Ahn Y., Zhou W., London W.B., McGrady P., et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978.
14. Goldsmith K.C., Lestini B.J., Gross M., Ip L., Bhumbla A., Zhang X., Zhao H., Liu X., Hogarty M.D. BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. Cell Death Differ. 2010, 17:872-882.
15. Gustafson W.C., Weiss W.A. Myc proteins as therapeutic targets. Oncogene 2010, 29:1249-1259.
16. Hamnér S., Arumäe U., Li-Ying Y., Sun Y.F., Saarma M., Lindholm D. Functional characterization of two splice variants of rat bad and their interaction with Bcl-w in sympathetic neurons. Mol. Cell. Neurosci. 2001, 17:97-106.
17. Hansford L.M., Thomas W.D., Keating J.M., Burkhart C.A., Peaston A.E., Norris M.D., Haber M., Armati P.J., Weiss W.A., Marshall G.M. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc. Natl. Acad. Sci. USA 2004, 101:12664-12669.
18. Hemann M.T., Lowe S.W. The p53-Bcl-2 connection. Cell Death Differ. 2006, 13:1256-1259.
19. Heuckmann J.M., Hölzel M., Sos M.L., Heynck S., Balke-Want H., Koker M., Peifer M., Weiss J., Lovly C.M., Grütter C., et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin. Cancer Res. 2011, 17:7394-7401.
20. Janoueix-Lerosey I., Lequin D., Brugières L., Ribeiro A., de Pontual L., Combaret V., Raynal V., Puisieux A., Schleiermacher G., Pierron G., et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970.
21. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., Ou S.H., Dezube B.J., Jänne P.A., Costa D.B., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363:1693-1703.
22. Liu Q., Wang J., Kang S.A., Thoreen C.C., Hur W., Ahmed T., Sabatini D.M., Gray N.S. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J. Med. Chem. 2011, 54:1473-1480.
23. Marshall G.M., Liu P.Y., Gherardi S., Scarlett C.J., Bedalov A., Xu N., Iraci N., Valli E., Ling D., Thomas W., et al. SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet. 2011, 7:e1002135.
24. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N. Engl. J. Med. 1999, 341:1165-1173. Children's Cancer Group.
25. Mossé Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935.
26. Murphy D.J., Junttila M.R., Pouyet L., Karnezis A., Shchors K., Bui D.A., Brown-Swigart L., Johnson L., Evan G.I. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 2008, 14:447-457.
27. Otto T., Horn S., Brockmann M., Eilers U., Schüttrumpf L., Popov N., Kenney A.M., Schulte J.H., Beijersbergen R., Christiansen H., et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009, 15:67-78.
28. National Cancer Institute. (2005). Surveillance, Epidemiology and End Results Database. http://seer.cancer.gov/publications/childhood/sympathetic.pdf.
29. Palmer R.H., Vernersson E., Grabbe C., Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem. J. 2009, 420:345-361.
30. Pelengaris S., Khan M., Evan G. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2002, 2:764-776.
31. Penn L.J., Brooks M.W., Laufer E.M., Land H. Negative autoregulation of c-myc transcription. EMBO J. 1990, 9:1113-1121.
32. Pulford K., Morris S.W., Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J. Cell. Physiol. 2004, 199:330-358.
33. Sasaki T., Okuda K., Zheng W., Butrynski J., Capelletti M., Wang L., Gray N.S., Wilner K., Christensen J.G., Demetri G., et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010, 70:10038-10043.
34. Schönherr C., Ruuth K., Kamaraj S., Wang C.L., Yang H.L., Combaret V., Djos A., Martinsson T., Christensen J.G., Palmer R.H., Hallberg B. Anaplastic lymphoma kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene 2012, Jan 30. [Epub ahead of print].
35. Schwab M., Varmus H.E., Bishop J.M., Grzeschik K.H., Naylor S.L., Sakaguchi A.Y., Brodeur G., Trent J. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature 1984, 308:288-291.
36. Sears R., Nuckolls F., Haura E., Taya Y., Tamai K., Nevins J.R. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000, 14:2501-2514.
37. Seeger R.C., Brodeur G.M., Sather H., Dalton A., Siegel S.E., Wong K.Y., Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 1985, 313:1111-1116.
38. Shachaf C.M., Gentles A.J., Elchuri S., Sahoo D., Soen Y., Sharpe O., Perez O.D., Chang M., Mitchel D., Robinson W.H., et al. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res. 2008, 68:5132-5142.
39. Sjostrom S.K., Finn G., Hahn W.C., Rowitch D.H., Kenney A.M. The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev. Cell 2005, 9:327-338.
40. Soucek L., Evan G.I. The ups and downs of Myc biology. Curr. Opin. Genet. Dev. 2010, 20:91-95.
41. Vernersson E., Khoo N.K., Henriksson M.L., Roos G., Palmer R.H., Hallberg B. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr. Patterns 2006, 6:448-461.
42. Weiss W.A., Aldape K., Mohapatra G., Feuerstein B.G., Bishop J.M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997, 16:2985-2995.
43. Wierstra I., Alves J. The c-myc promoter: still MysterY and challenge. Adv. Cancer Res. 2008, 99:113-333.
44. Zhu S., Lee J.S., Guo F., Shin J., Perez-Atayde A.R., Kutok J.L., Rodig S.J., Neuberg D.S., Helman D., Feng H., et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 2012, 21:362-373.